Lecture: Translating mechanisms to benefits: How can we explain the cardiovascular benefits of new diabetes drugs?

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Two choices of drugs that reduce CV risk in T2DM
Two choices of drugs that reduce CV risk in T2DM
CDMC 2018: Shifting gears in the management of diabetes and CVD
Two choices of drugs that reduce CV risk in T2DM
- Prof. John Deanfield, MD
Benefits of GLP-1RA and SGLT2-i in primary and secondary prevention of CVD in T2DM
Benefits of GLP-1RA and SGLT2-i in primary and secondary prevention of CVD in T2DM
CDMC 2018: Shifting gears in the management of diabetes and CVD
Benefits of GLP-1RA and SGLT2-i in primary and secondary prevention of CVD in T2DM
- Prof. Eduard Montanya, MD
Lecture: The GLP1 landscape - refining our understanding
Lecture: The GLP1 landscape - refining our understanding
CDMC 2018: Shifting gears in the management of diabetes and CVD
Lecture: The GLP1 landscape - refining our understanding
Lecture: Clinical trials in T2DM & CVD: Review of key outcomes with GLP-1 RA and SGLT2i
Lecture: Clinical trials in T2DM & CVD: Review of key outcomes with GLP-1 RA and SGLT2i
CDMC 2018: Shifting gears in the management of diabetes and CVD
Lecture: Clinical trials in T2DM & CVD: Review of key outcomes with GLP-1 RA and SGLT2i
- Prof. Eduard Montanya Barcelona